Drug Combo Shows Benefits in Rare, Aggressive Kidney Cancer

By News Health
2 months Ago

(MedPage Today) — The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.
Among 41…

Source link : https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/117022

Author :

Publish date : 2025-08-15 18:21:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Biologics May Promote Structural Lung Changes in COPD

Dolly Parton's Health Concern; HHS to Furlough 41% of Workers? Tylenol Lawsuit Boost

Trump's Remarks on Autism Evoke Anger and Hope in Autistic People and Their Families

Patient Dialogues: Inflammation and Dietary Interventions

Clean Air, Green Spaces May Guard Kids Against Hypertension

Covid cases rising with new variants 'Nimbus' and 'Stratus'